HUE056045T2 - Rifaximin alfa és delta tartalmú gyógyászati készítmény - Google Patents
Rifaximin alfa és delta tartalmú gyógyászati készítményInfo
- Publication number
- HUE056045T2 HUE056045T2 HUE18193241A HUE18193241A HUE056045T2 HU E056045 T2 HUE056045 T2 HU E056045T2 HU E18193241 A HUE18193241 A HU E18193241A HU E18193241 A HUE18193241 A HU E18193241A HU E056045 T2 HUE056045 T2 HU E056045T2
- Authority
- HU
- Hungary
- Prior art keywords
- delta
- pharmaceutical composition
- composition containing
- containing rifaximin
- rifaximin alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16162415 | 2016-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE056045T2 true HUE056045T2 (hu) | 2022-01-28 |
Family
ID=55637248
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE17712970A HUE040253T2 (hu) | 2016-03-24 | 2017-03-22 | Rifaximin alfa&deltát tartalmazó gyógyászati készítmény |
HUE18193241A HUE056045T2 (hu) | 2016-03-24 | 2017-03-22 | Rifaximin alfa és delta tartalmú gyógyászati készítmény |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE17712970A HUE040253T2 (hu) | 2016-03-24 | 2017-03-22 | Rifaximin alfa&deltát tartalmazó gyógyászati készítmény |
Country Status (7)
Country | Link |
---|---|
US (1) | US10576065B2 (hu) |
EP (2) | EP3434265B1 (hu) |
ES (2) | ES2893869T3 (hu) |
HU (2) | HUE040253T2 (hu) |
PL (2) | PL3294270T3 (hu) |
TR (1) | TR201816080T4 (hu) |
WO (1) | WO2017162725A1 (hu) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1698630B1 (en) | 2005-03-03 | 2014-09-03 | ALFA WASSERMANN S.p.A. | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
SI3546464T1 (sl) | 2014-05-12 | 2020-09-30 | Alfasigma S.P.A. | Priprava in uporaba rifaksimina v kristalni obliki TAU solvatiranega z degme |
US10576065B2 (en) | 2016-03-24 | 2020-03-03 | Sandoz Ag | Pharmaceutical composition containing rifaximin alpha and delta |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
EP1698630B1 (en) | 2005-03-03 | 2014-09-03 | ALFA WASSERMANN S.p.A. | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
ITBO20050123A1 (it) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
CA2761602C (en) * | 2009-05-11 | 2015-07-07 | Ratiopharm Gmbh | Desfesoterodine in the form of a tartaric acid salt |
IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
US9018225B1 (en) * | 2013-07-26 | 2015-04-28 | Novel Laboratories | Rifaximin crystalline forms and methods of preparation thereof |
EP2927235B1 (en) | 2014-03-31 | 2017-02-08 | Euticals S.P.A. | Polymorphic mixture of rifaximin and its use for the preparation of solid formulations |
ES2738024T5 (es) | 2016-03-24 | 2022-10-24 | Sandoz Ag | Composición estable al almacenamiento que comprende rifaximina alfa |
US10576065B2 (en) | 2016-03-24 | 2020-03-03 | Sandoz Ag | Pharmaceutical composition containing rifaximin alpha and delta |
-
2017
- 2017-03-22 US US15/738,663 patent/US10576065B2/en active Active
- 2017-03-22 TR TR2018/16080T patent/TR201816080T4/tr unknown
- 2017-03-22 HU HUE17712970A patent/HUE040253T2/hu unknown
- 2017-03-22 ES ES18193241T patent/ES2893869T3/es active Active
- 2017-03-22 WO PCT/EP2017/056797 patent/WO2017162725A1/en active Application Filing
- 2017-03-22 EP EP18193241.9A patent/EP3434265B1/en active Active
- 2017-03-22 PL PL17712970T patent/PL3294270T3/pl unknown
- 2017-03-22 PL PL18193241T patent/PL3434265T3/pl unknown
- 2017-03-22 EP EP17712970.7A patent/EP3294270B1/en not_active Revoked
- 2017-03-22 HU HUE18193241A patent/HUE056045T2/hu unknown
- 2017-03-22 ES ES17712970T patent/ES2700423T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
US10576065B2 (en) | 2020-03-03 |
EP3294270A1 (en) | 2018-03-21 |
HUE040253T2 (hu) | 2019-02-28 |
PL3294270T3 (pl) | 2019-02-28 |
PL3434265T3 (pl) | 2021-12-13 |
ES2700423T3 (es) | 2019-02-15 |
EP3434265B1 (en) | 2021-07-07 |
ES2893869T3 (es) | 2022-02-10 |
EP3294270B1 (en) | 2018-09-12 |
US20180169076A1 (en) | 2018-06-21 |
TR201816080T4 (tr) | 2018-11-21 |
WO2017162725A1 (en) | 2017-09-28 |
EP3434265A1 (en) | 2019-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL265360A (en) | Pharmaceutical composition | |
EP3549589A4 (en) | PHARMACEUTICAL COMPOSITION WITH MITOCHONDRIA | |
IL265260B (en) | pharmaceutical preparations | |
IL262654A (en) | Pharmacy preparation | |
IL265349A (en) | Pharmaceutical composition | |
IL267224A (en) | Pharmaceutical preparations containing insulin | |
PL3421038T3 (pl) | Związek naftyrydyny, kompozycja farmaceutyczna i ich zastosowanie | |
SI3278801T1 (sl) | Farmacevtski sestavek, ki vsebuje mirabegron | |
IL263040A (en) | Pharmaceutical composition comprising eteplirsen | |
PL3373914T5 (pl) | Trwała przy przechowywaniu kompozycja zawierająca rifaksyminę alfa | |
IL267136A (en) | Pharmaceutical composition containing celecoxib | |
HUE040253T2 (hu) | Rifaximin alfa&deltát tartalmazó gyógyászati készítmény | |
PL3454838T3 (pl) | Kompozycja farmaceutyczna | |
GB201615917D0 (en) | Pharmaceutical composition | |
GB201615914D0 (en) | Pharmaceutical composition | |
GB201615910D0 (en) | Pharmaceutical composition | |
ZA201902767B (en) | Pharmaceutical compositions comprising rifaximin | |
IL265436B (en) | Pharmacy preparation | |
PL3424500T3 (pl) | Kompozycja farmaceutyczna zawierająca famitynib | |
IL265428A (en) | Pharmaceutical composition | |
PT3329939T (pt) | Composição farmacêutica sólida à prova de abuso | |
PT3476391T (pt) | Composição farmacêutica que compreende arginina para utilização no tratamento da doença de poliq | |
GB201620519D0 (en) | Pharmaceutical composition | |
GB201620517D0 (en) | Pharmaceutical composition | |
GB201620516D0 (en) | Pharmaceutical composition |